N-(2-Chloro-6-Methylphenyl)-2-[(6-Chloro-2-Methyl-4-Pyrimidinyl)Amino]-5-Thiazolecarboxamide

Designated by CAS 302964-08-5 and often catalogued as a dasatinib penultimate intermediate, N-(2-chloro-6-methylphenyl)-2-[(6-chloro-2-methyl-4-pyrimidinyl)amino]-5-thiazolecarboxamide is a non-hygroscopic, off‑white to pale‑yellow crystalline solid supplied in lot sizes typically ranging from 500 g to 25 kg. Its molecular formula is C₁₆H₁₃Cl₂N₅OS, molecular weight 394.28 g/mol. The compound serves as the immediate precursor to dasatinib free base, wherein the 6‑chloro substituent on the pyrimidine ring is displaced by 2‑piperazin‑1‑ylethanol in a final‑stage nucleophilic aromatic substitution. This convergent intermediate is obtained from a three‑component Hantzsch‑type thiazole synthesis followed by chlorination and amidation, and it is routinely manufactured under ICH Q7 GMP conditions when destined for registration‑batch active pharmaceutical ingredient preparation. The following two tables summarise representative analytical acceptance criteria and a side‑by‑side comparison with structurally proximal analogues that are frequently confused in procurement workflows.

Storage is specified at 2–8 °C in tightly sealed, argon‑flushed triple‑laminated foil bags containing desiccant. Prolonged exposure to relative humidity above 60% at ambient temperature initiates slow hydrolysis of the 6‑chloro group, generating the corresponding 6‑hydroxy pyrimidinone impurity, which co‑elutes under standard reversed‑phase gradients and can elevate single‑impurity readings above the 0.10% threshold required by downstream drug‑substance monographs.

Purity Specifications and the Impact of Trace Metal Catalysts on Downstream Crystallinity

Although HPLC purity regularly exceeds 99.0% in commercial lots, the most consequential quality attribute for the final substitution step is residual palladium content. The penultimate amidation is frequently carried out via a Buchwald–Hartwig coupling between 2‑amino‑5‑thiazolecarboxylic acid derivative and 2,6‑dichlorotoluene using Pd₂(dba)₃/Xantphos catalyst systems. Inadequate post‑reaction scavenging with trimercaptotriazine‑functionalised silica or activated carbon leaves soluble palladium species that persist into the dasatinib free‑base stream, where they catalyse debenzylation‑type side reactions during the final hydrogenation or salt formation, generating quantities of des‑chloro and des‑methyl analogues above ICH Q3B qualification thresholds. Therefore, a validated ICP‑MS limit of ≤ 10 ppm Pd is enforced, and occasional batches exceeding 8 ppm are re‑crystallised from ethyl acetate/cyclohexane to bring the level below 5 ppm.

How Does the 6‑Chloro Substituent Govern Reactivity Toward Piperazine Nucleophiles?

The synthetic utility of the intermediate hinges on the leaving‑group aptitude of the chlorine atom at the pyrimidine 6‑position. In a typical coupling, the compound (1.0 eq) is dissolved in anhydrous 1‑methyl‑2‑pyrrolidinone (NMP, 5.0–6.0 L/kg of intermediate) and treated with 1.15–1.20 eq of 2‑piperazin‑1‑ylethanol and 2.5 eq of N,N‑diisopropylethylamine under nitrogen. The mixture is heated to 85 ± 3 °C and maintained for 12–16 h until HPLC shows ≤ 0.15% residual starting material. Process‑scale manufacturing in glass‑lined reactors (EN 14420‑2 rated) employs jacket temperature control with a maximum heating ramp of 0.5 K/min to avoid exotherms that can spike above 95 °C, where the liberated chloride ion promotes ring degradation leading to a brown colouration and a 2–4% yield loss.

The kinetic profile under these conditions follows a pseudo‑first‑order rate law with respect to the chloro intermediate (observed k ~ 0.18 h⁻¹ at 85 °C), and the activation energy derived from Arrhenius analysis of pilot‑plant data across 70–90 °C is approximately 62 kJ/mol. Competing hydrolysis, forming 6‑hydroxy‑2‑methylpyrimidine by‑product, exhibits a lower activation barrier (≈48 kJ/mol), so strict moisture control is imperative. Karl Fischer titrations of the NMP solution before charging the nucleophile consistently show water content below 0.05%. Inadequate drying of the reactor or use of nitrogen with > 10 ppm moisture has been linked to hydroxy impurity levels exceeding 0.8% in the crude dasatinib, which cannot be reliably purged by the downstream recrystallisation from ethanol/water.

When compared with the analogous 6‑fluoro pyrimidine derivative, the chloro intermediate provides a wider processing window. The 6‑fluoro congener reacts >10‑fold faster at 40 °C, but its sensitivity to hydrolysis is so acute that even 0.02% water in the solvent raises the hydroxy impurity beyond 2% within the first two hours, making kilogram‑scale handling impractical with standard plant equipment. Conversely, the 6‑bromo analogue is too sluggish at 85 °C and requires >48 h residence time, during which thermal decomposition of the thiazole ring accelerates. The 6‑chloro intermediate therefore represents the empirically optimised balance between adequate reaction rate at industrially accessible temperatures and tolerance to residual moisture, as confirmed by multiple 50 kg validation batches.

Differentiation from N‑Deschloro and Fully Substituted Piperazinyl Analogues

Procurement confusion between this penultimate intermediate and closely related substances can introduce a 4–8 week supply‑chain delay if the incorrect material is issued to the final coupling stage. The principal point of differentiation is the pyrimidine substitution pattern. The N‑deschloro variant, N‑(2‑chloro‑6‑methylphenyl)‑2‑[(2‑methyl‑4‑pyrimidinyl)amino]‑5‑thiazolecarboxamide, lacks the chlorine at the 6‑position and is therefore unreactive toward piperazine nucleophiles under non‑forcing conditions. It is a known process impurity that co‑crystallises with the chloro intermediate if recrystallisation solvent ratios are not carefully controlled, and its presence at >0.15% in the charging assay is sufficient to raise unreacted starting material in the dasatinib step above the 0.10% limit defined in the USP monograph for dasatinib tablets. The N‑deschloro impurity can be detected via HPLC with a retention time shift of approximately −0.7 min relative to the main peak under a C18, 150 × 4.6 mm, 3 µm column with a phosphate buffer‑acetonitrile gradient.

The final fully substituted analogue, dasatinib free base (CAS 302962‑49‑8), differs in both physical properties and storage requirements. Dasatinib free base is a dihydrate‑forming solid with a melting endotherm at 280–285 °C and is typically a white to faintly yellow powder, whereas the chloro intermediate melts with decomposition at a significantly lower temperature, as listed in Table 2. In the manufacturing environment, the intermediate is handled as a non‑potent synthetic building block, avoiding the containment protocols required for the biologically active final substance. The following table captures the operational distinctions that affect material requisition and warehousing.

During pilot‑scale campaigns at the 50–100 L scale, the distinction between the chloro intermediate and the N‑deschloro analogue has been enforced by commissioning two dedicated, non‑interchangeable charging ports in the isolator suite. Material movements are verified by the quality‑control laboratory using a 10‑minute HPLC identity check with diode‑array confirmation at 254 nm and 280 nm absorbance ratio, which unambiguously discriminates the two species even in the presence of 5% co‑contamination. The receiving area for the final coupling step mandates a positive identity release before the glove‑valve is unlocked to introduce the solid into the NMP‑filled reactor. In one documented deviation during a technology transfer batch, delivery of the des‑chloro material led to a stalled reaction that was only detected after 8 h of heating when in‑line ReactIR showed no disappearance of the C–Cl band at 1065 cm⁻¹; the investigation reaffirmed the necessity of the identity protocol and the vulnerability of the supply chain when purveyors use ambiguous nomenclature.